Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current or former cigarette smokers with a cigarette smoking history of at least 10 pack-years~* A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable airway obstruction.~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within three months prior to Visit 1~* Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Visit 1.~* Patients with any clinically significant respiratory conditions other than COPD~* Clinical history that suggests that the patient has asthma as opposed to COPD~* Chronic use of oxygen therapy ≥ 15 hours/day~* Patients with clinically significant cardiovascular conditions~* Patients with uncontrolled infection that may place the patient at risk resulting from human immunodeficiency virus (HIV), active hepatitis and/or patients with diagnosed active tuberculosis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics,~* Patients with Stage II hypertension, defined as systolic pressure of 160 and above, and/or diastolic pressure of 100 and above~* Current diagnosis of cancer other than basal or squamous cell skin cancer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
- 2 (Type: ACTIVE_COMPARATOR): Inhaled formoterol fumarate 12 μg, twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).